Can ecstasy tame the bad trips of magic mushrooms?

NCT ID NCT06884514

Completed Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 1 study in 24 healthy adults tested whether taking MDMA (the drug in ecstasy) alongside psilocybin (the active ingredient in magic mushrooms) reduces anxiety and negative feelings while boosting positive mood and trust. Researchers measured mood, blood pressure, heart rate, and body temperature to see if the combination is safer and more pleasant than psilocybin alone. The goal is to gather knowledge that could eventually improve psychedelic-assisted therapy for conditions like depression.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: psilocybin and MDMA
What this could lead to: If it works, this could point toward safer psychedelic-assisted therapy by using MDMA to reduce anxiety and negative experiences from psilocybin.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. The combination may still cause side effects or not translate to therapeutic settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY

Contacts and locations

Locations

University Hospital Basel

Basel, 4031, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.